Pentoxifylline
Company: Faulding, Mylan Laboratories
Approval Status: Approved July 1997
Treatment for: chronic occlusive arterial disease
Areas: Cardiology/Vascular Diseases
| General Information | Clinical Results | Mechanism of Action |
General Information
Pentoxifylline is a 400 mg extended release tablet and the generic equivalent of Trental. It is being marketed by Hoechst Marion Roussel. Pentoxifylline extended release tablets are indicated for the treatment of leg pain caused chronic occlusive arterial disease of the limbs. Patient walking distance and daily activities are limited by the disease. Both Faulding and Mylan are now manufacturing Pentoxifylline.
Clinical Results
In a comparison between aspirin and pentoxifylline in the elderly, the level of pain did not change significantly with either aspirin or pentoxifylline, but patient’s walking distance was extended with the pentoxifylline group.
Mechanism of Action
Pentoxifylline increases red blood cell flexibility and improves blood flow.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
